News

NEW YORK, NY – October 15, 2020 – Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today the pricing of the secondary offering of 17,343,037 shares of its Class A ordinary shares by selling shareholders in an underwritten public offering pursuant to a registration statement on Form S-1

NEW YORK , Oct. 15, 2020 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2020 of $0.15 per class A share. The dividend will be paid on December 15, 2020 , to shareholders of record at the close of

NEW YORK , Oct. 13, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (the “Company”) (Nasdaq: RPRX) announced today that certain selling shareholders intend to offer an aggregate 17,343,037 of the Company's Class A ordinary shares in an underwritten public offering.

NEW YORK, NY, September 2, 2020 - The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2020 of $0.15 per class A share. The dividend will be paid on September 30, 2020, to shareholders of record at the close of business on

NEW YORK, NY – September 2, 2020 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has closed an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”): $1 billion aggregate principal amount of 0.75% Senior Notes due 2023; $1 billion

NEW YORK, NY - August 25, 2020 – Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $6 billion senior unsecured notes, comprised of the following tranches (collectively, the “Notes”): $1 billion aggregate principal amount of 0.75% Senior Notes due 2023; $1 billion aggregate

NEW YORK (NY) - August 19, 2020 – Royalty Pharma plc announced today that it intends to offer, subject to market and other conditions, senior unsecured notes in multiple tranches (the “Notes”) in a private offering exempt from registration in accordance with Rule 144A and Regulation S under the

Strong double-digit growth in Net cash provided by operating activities (GAAP) and Adjusted Cash Receipts (1) (non-GAAP)   Company introduces 2020 guidance: Adjusted Cash Receipts expected to be $1,720 to $1,760 million   $1.7 billion of new acquisitions announced in 2020 NEW YORK , Aug.

- Biohaven will receive up to $250 million to fund zavegepant’s development in migraine and non-migraine indications - Royalty Pharma to acquire up to a 3% royalty for zavegepant, a 0.4% royalty of Nurtec™ ODT and success-based milestone payments - Royalty Pharma will purchase   new   Commercial

NEW YORK , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma (Nasdaq: RPRX) today announced the appointments of Henry A. Fernandez and Ted W. Love , M.D. to the company's Board of Directors, effective immediately. Mr. Fernandez is Chairman and Chief Executive Officer of MSCI Inc., a leading global